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Abstract
Genetics strongly implicate the amyloid β-peptide (Aβ) in the pathogenesis of Alzheimer’s 
disease. Dominant missense mutation in the presenilins and the amyloid precursor protein (APP) 
cause early-onset familial Alzheimer’s disease (FAD). As presenilin is the catalytic component of 
the γ-secretase protease complex that produces Aβ from APP, mutation of the enzyme or substrate 
that produce Aβ leads to FAD. However, the mechanism by which presenilin mutations cause FAD 
has been controversial, with gain of function and loss of function offered as binary choices. This 
overview will instead present the case that presenilins are dysfunctional in FAD. γ-Secretase is a 
multi-functional enzyme that proteolyzes the APP transmembrane domain in a complex and 
processive manner. Reduction in a specific function—the carboxypeptidase trimming of initially 
formed long Aβ peptides containing most of the transmembrane domain to shorter secreted forms
—is an emerging common feature of FAD-mutant γ-secretase complexes.
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Introduction
The deposition of extracellular amyloid plaques and neurofibrillary tangles in the brain are 
cardinal pathological features of Alzheimer’s disease (AD) (Goedert and Spillantini, 2006). 
The former are composed primarily of the amyloid β-peptide (Aβ), while the latter are 
comprised of filaments of the otherwise microtubule-associated protein tau. The general 
consensus is that Aβ and tau are both critical to the neurodegenerative process of AD, with 
Aβ being upstream of tau in the pathway. However, the deposits per se may not be 
pathogenic. Indeed, amyloid plaques numbers or location do not seem to correlate with 
disease onset or progression. (Lue et al., 1999; McLean et al., 1999; Naslund et al., 2000). In 
the past two decades, evidence has mounted suggesting that soluble oligomeric forms of Aβ 
cause synaptic dysfunction and are more detrimental than the plaques (Masters and Selkoe, 
2012). Nevertheless, the specific pathogenic form of Aβ remains unknown, and the 
molecular means by which pathogenic Aβ triggers downstream synapto- and neurotoxic 
events are unclear (Benilova et al., 2012). Regardless of the exact forms responsible for 
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dominant familial AD (FAD) clearly point to alterations in Aβ being sufficient for 
neurodegenerative disease (Rademakers et al., 2012; Tanzi and Bertram, 2005).
APP Processing by Secretases
Aβ is a 38–43 amino acid secreted peptide derived from the amyloid β-protein precursor 
(APP), a 695–770 amino acid single-pass transmembrane protein (Masters and Selkoe, 
2012) (Figure 1). The large extracellular/lumenal domain of APP is shed from the membrane 
by either α-secretase or β-secretase activity. α-Secretases are membrane-anchored 
metalloproteases that cut APP within the Aβ region, thus precluding Aβ production, leaving 
an APP C-terminal fragment (APP CTF-α) in the membrane. β-Secretase cuts further away 
from the transmembrane domain to generate the N-terminal region of Aβ as part of APP 
CTF-β. Both APP CTF-α and -β are subsequently cleaved by γ-secretase to produce p3 
(from CTF-α) and Aβ (from CTF-β) and the APP intracellular domain (AICD). The 
biological roles of APP and its proteolytic fragments are largely unknown (Muller and 
Zheng, 2012).
The predominant form of Aβ is composed of 40 amino acids, while ~5–10% is 42 amino 
acids, with the difference at the C-terminus, which is formed from the transmembrane 
domain of APP by γ-secretase (De Strooper et al., 2012). Although Aβ42 is a minor variant, 
this peptide is much more prone to aggregation than is Aβ40 (Jarrett et al., 1993) and is the 
primary component of the amyloid plaques in the AD brain (Iwatsubo et al., 1994). Aβ42 
has been extensively studied for many years to understand the aggregation process; the 
structure of the monomer, oligomers, protofibrils, fibrils and plaques (Roychaudhuri et al., 
2009); the neurotoxic species and possible neurotoxic pathways (Mucke and Selkoe, 2012). 
The current dogma is that one or more soluble oligomeric forms of Aβ42 are the neurotoxic 
entity, although this leading hypothesis has been met with reasonable skepticism (Benilova 
et al., 2012).
Genetics of Familial AD
The strongest evidence for the pathogenicity of Aβ in AD comes from genetic studies of 
early-onset familial AD (FAD) (Tanzi and Bertram, 2005). Dominant missense mutations in 
the APP gene are associated with FAD. Although APP is a large membrane protein, all the 
FAD mutations in APP are found in and around the small Aβ region and alter the production 
or aggregation propensity of Aβ peptides. An FAD double mutation found immediately 
proximal to the N-terminus of Aβ is cleaved more effectively by β-secretase, leading to 
increased Aβ production (Cai et al., 1993; Citron et al., 1992). Recently, a protective 
mutation in this region was discovered, substantially reducing the risk of developing AD, 
even when carriers reach their 80s or 90s (Jonsson et al., 2012). This protective mutation 
decreases cleavage by β-secretase, leading to lower production of Aβ. Other mutations 
found within the Aβ sequence increase its aggregation propensity [e.g., (Massi et al., 2002)]. 
Still others, found near the γ-secretase cleavage site, lead to increased ratios of Aβ42 to 
Aβ40 [e.g., (Suzuki et al., 1994)], thereby increasing the aggregation propensity as well.
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Dominant FAD missense mutations are also found in genes encoding presenilin-1 and −2 
(PS1 and PS2), multi-pass membrane proteins that comprise the catalytic component of γ-
secretase (Tanzi and Bertram, 2005). Over 200 such mutations have been identified, and 
some can cause AD even before age 30 (Moehlmann et al., 2002). Like those FAD 
mutations in APP near the γ-secretase cleavage site, FAD-mutant PS1 and PS2 lead to 
increased Aβ42/Aβ40 and overall increased aggregation propensity (Borchelt et al., 1996; 
Citron et al., 1997; Tomita et al., 1997; Xia et al., 1997). Other than the strong heredity 
factor and early age of onset, these dominant missense mutations in APP and the presenilins 
result in a similar course of disease onset, progression and brain pathology, (including 
neurofibrillary tangles containing tau filaments) that are observed in sporadic, late-onset AD.
While the FAD cases are very rare, because the presentation, course and pathology are 
similar to sporadic AD, the mechanisms by which the FAD mutations result in 
neurodegeneration and dementia should be informative about the pathogenic mechanism of 
AD in general. For this reason, Aβ and Aβ production, particularly via proteolytic cleavage 
by γ-secretase, has been such a major focus in the field. FAD mutations alter Aβ or Aβ 
production, with the large majority of these mutations found in the presenilins, which alter 
γ-secretase activity to increase Aβ propensity to aggregation. In the next section, we discuss 
the details of γ-secretase biochemistry and the effects of FAD mutations on its activity.
The γ-Secretase Complex
As mentioned above, presenilin is the catalytic component of γ-secretase. Specifically, two 
completely conserved transmembrane aspartic acids are required for proteolytic activity 
(Wolfe et al., 1999), placing γ-secretase in the aspartyl protease family, even though it 
otherwise bears no resemblance to the many well-known soluble aspartyl proteases (e.g., 
pepsin, renin, HIV protease). The presence of the two transmembrane aspartates within a 
multi-pass membrane protein is consistent with the ability of γ-secretase to cleave within the 
transmembrane domain of APP in generating Aβ. Three other membrane proteins are 
components of γ-secretase along with presenilin: nicastrin, Aph-1 and Pen-2 (Edbauer et al., 
2003; Kimberly et al., 2003; Takasugi et al., 2003). After all four components assemble in 
the endoplasmic reticulum, presenilin undergoes autoproteolysis (Fukumori et al., 2010; 
Wolfe et al., 1999) into an N-terminal fragment (NTF) and C-terminal fragment (CTF) to 
generate the active γ-secretase complex (Figure 1). Each of these presenilin subunits 
contributes one of the catalytic aspartates to the active site (Esler et al., 2000; Li et al., 
2000).
γ-Secretase has many more substrates besides APP (Haapasalo and Kovacs, 2011). The 
most important of these is signaling from the Notch family of receptors (Selkoe and Kopan, 
2003). Notch receptors are single-pass membrane proteins like APP, and proteolytic 
processing of Notch, triggered by interaction with cognate ligands on neighboring cells, 
leads to release of its intracellular domain. This released domain then translocates to the 
nucleus and interacts with specific transcription factors that control the expression of genes 
involved in cell differentiation. These signaling pathways, particularly from Notch1 
receptors, are essential to proper development in all multi-cellular animals.
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Processive Proteolysis by γ-Secretase
Presenilin mutations that cause FAD were first identified over 20 years ago, but the 
pathogenic mechanisms remain controversial and unknown. One hypothesis is that these 
dominant mutations cause a gain of function, specifically an increase in the ratio of 42- or 
43-residue amyloid β-peptides (Aβ42 or Aβ43) to the 40-residue form (Aβ40) (Selkoe and 
Hardy, 2016), while an alternative hypothesis argues that loss of proteolytic function of γ-
secretase is responsible for pathogenesis (Kelleher and Shen, 2017). However as we will 
discuss, presenilin and the γ-secretase complex have multiple proteolytic functions and 
produce other Aβ peptides ranging from 38–49 amino acids. Gain of function and loss of 
function are genetic terms that do not address the biochemical complexity of proteolytic 
processing of APP and other substrates by γ-secretase.
In recent years, the proteolysis of APP substrates by γ-secretase has been revealed to be 
much more complicated than initially believed. As noted earlier, secreted forms of Aβ range 
from 38–43 amino acids. However, identification of the N-terminus of the other product of 
γ-secretase cleavage of APP, AICD, revealed that proteolysis also occurs between residues 
49 and 50 (Aβ numbering) (Weidemann et al., 2002), close to the cytosolic end of the 
transmembrane domain, and this cleavage event is also γ-secretase-dependent. Mass 
spectrometric analysis of AICD showed that a minor degree of cleavage also occurs between 
residues 48 and 49 (Sato et al., 2003) (Figure 2). Interestingly, FAD mutations were found to 
increase the proportion of AICD beginning at residue 49 over that beginning at residue 50, 
similar to the ability of these mutations to increase Aβ42 over Aβ40 (Sato et al., 2003). 
Thus, γ-secretase cleaves the APP transmembrane domain at least twice, and both of these 
cleavage events are altered by FAD mutations.
In the analysis of γ-secretase cleavage products, however, some residues were unaccounted 
for. Most Aβ peptides are Aβ40, while most AICD begins at residue 50. The discovery of 
longer forms of Aβ was an important step in solving this mystery. Modified gel 
electrophoresis methods allowed resolution of Aβ peptides to one amino acid resolutions, 
and such analysis revealed Aβ45, Aβ46, Aβ48 and Aβ49 (Kakuda et al., 2006; Qi-Takahara 
et al., 2005). Thus, Aβ peptides ranging all the way to where AICD begins suggested that 
initial proteolysis occurs near the C-terminal end of the transmembrane domain, producing 
AICD and either Aβ48 or Aβ49. These long Aβ peptides are then trimmed through a 
carboxypeptidase function of γ-secretase to produce the secreted forms of Aβ (Funamoto et 
al., 2004; Kakuda et al., 2006) (Figure 2) Further studies refined this idea by suggesting two 
pathways for Aβ production: Aβ49→Aβ46→Aβ43→Aβ40 and 
Aβ48→Aβ45→Aβ42→Aβ38 (Yagishita et al., 2008) (Figure 3). The expected tri- and 
tetrapeptides formed in this process have been detected by mass spectrometry in cell-free γ-
secretase assays (Takami et al., 2009). Interestingly, the small levels of long Aβ peptides 
released by the protease complex before complete trimming are found in cell membrane 
fractions (Qi-Takahara et al., 2005), as might be expected given that these peptides contain 
most of the APP transmembrane domain.
Reports of dissociation between Aβ42 and Aβ38 led to doubts about the precursor-product 
relationship between these two peptides (Czirr et al., 2008; Page et al., 2008), and other 
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reports of dissociation between Aβ and AICD have questioned the carboxypeptidase activity 
of γ-secretase and the dual-pathway model [e.g., (He et al., 2010)]. However, as mentioned 
above, unambiguous evidence that γ-secretase converts Aβ42 to Aβ38 has come from in 
vitro assays (Okochi et al., 2013). Furthermore, a dissociation of Aβ and AICD is a 
stoichiometric impossibility, as cleavage of APP CTF-β must give one Aβ molecule for 
every AICD, and this has been formally proven to be the case through careful quantification 
(Kakuda et al., 2006). Moreover, we have found that synthetic peptides ranging from Aβ45-
Aβ49 are converted to Aβ40 and Aβ42 by purified γ-secretase and in the same proportions 
as expected from the dual-pathway model (Fernandez et al., 2014). These results were seen 
whether using detergent solubilized γ-secretase preparations or purified protease complex 
reconstituted into lipid vesicles. Thus, the carboxypeptidase activity of γ-secretase and the 
dual-pathway model are unambiguously established as intrinsic properties of the enzyme 
independent of the membrane.
FAD γ-Secretases and Carboxypeptidase Activity
Recent findings on the more detailed effects of presenilin FAD mutations on Aβ production 
suggest how these mutations may cause disease. In a study from our lab (Quintero-Monzon 
et al., 2011), five different FAD PS1-mutant γ-secretase complexes were compared to wild 
type using in vitro assays and PAGE analysis of the range of Aβ peptides as well as AICD. 
Four of the five FAD mutations caused a reduction in AICD and total Aβ production 
compared to the wild-type enzyme, consistent with previous findings that the majority of 
PS1 mutations cause a “loss of function” in proteolysis. One of these mutations, however, 
produced AICD and Aβ to the same degree as the wild-type enzyme, demonstrating that 
such general reduction of proteolytic function is not essential for pathogenicity. However, all 
five mutations skewed Aβ production in favor of the longer forms (>Aβ42), suggesting that 
the mutations all caused a deficiency in the carboxypeptidase function of γ-secretase. 
Another report from the lab of Bart De Strooper (Chavez-Gutierrez et al., 2012) confirmed 
these findings, that presenilin FAD mutations do not necessarily inhibit general proteolysis 
by γ-secretase but do cause qualitative changes in the types of Aβ peptides produced, in 
favor of longer forms. We have further found that PS1 FAD-mutant γ-secretase complexes 
are dramatically deficient in their ability to trim Aβ48 and Aβ49 to Aβ40 and Aβ42 
(Fernandez et al., 2014), providing important confirmation of reduced carboxypeptidase 
function as the common feature of disease-causing γ-secretase, independent of initial 
cleavage of APP CTF-β to form AICD and Aβ48/49.
Collectively, these findings show that the increase in Aβ42-to-Aβ40 observed by presenilin 
FAD mutations may be a consequence of reduced trimming function. However, the 
relationship between these two Aβ peptides is not the only change. In general, the 
proportion of longer forms of Aβ, including membrane-associated forms Aβ45-Aβ49, are 
substantially increased, raising the question of what pathogenic role, if any, these Aβ 
peptides may play. In any event, the apparent reduction in carboxypeptidase function caused 
by presenilin FAD mutations suggests that therapeutic agents targeting γ-secretase should 
correct this biochemical defect; that is, rather than searching for inhibitors of γ-secretase, 
stimulators of the carboxypeptidase function should be sought. A class of γ-secretase 
modulators do this, but only for the last of the trimming step (e.g., Aβ42→Aβ38), making 
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their therapeutic potential entirely dependent on Aβ42 being the primary pathogenic species. 
A more general stimulator of γ-secretase carboxypeptidase activity might be more 
appropriate, as it would not depend on knowing exactly which form of Aβ is responsible for 
the cascade of events that result in neurotoxicity, neurodegeneration and dementia.
Pathogenic and Therapeutic Implications
Presenilin and the γ-secretase complex are central to the pathogenesis of AD, as dominant 
mutations in the presenilins alter γ-secretase activity and Aβ production and cause 
hereditary AD in midlife that is otherwise indistinguishable from sporadic, late-life AD. 
This membrane-embedded protease has been considered an AD therapeutic target for AD for 
over 15 years. Potent brain-penetrant inhibitors have been developed and brought into 
clinical trials. However, these compounds showed serious toxic effects due to inhibition of 
proteolysis and signaling from the Notch1 receptor (Coric et al., 2012; Doody et al., 2013). 
More worrisome, cognitive worsening was observed, which mouse models suggest may be 
due to increased levels of APP γ-secretase substrates (Mitani et al., 2012). Modulators of γ-
secretase have been discovered that selectively lower Aβ42 and some have entered clinical 
trials (Bursavich et al., 2016). Although these compounds are apparently safe, their potential 
to prevent or treat AD is dependent on Aβ42 being the primary pathogenic entity. New 
findings on the effects of AD-causing presenilin mutations reveal a common defect in 
carboxypeptidase function, resulting in increased proportions of other Aβ peptides, even 
longer than Aβ42. The pathogenicity of these longer Aβ peptides is unknown.
While possible roles of these long Aβ peptides in AD should be investigated, parallel efforts 
to identify compounds that rescue the deficient carboxypeptidase function of FAD-mutant γ-
secretase complexes may lead to the development of effective therapeutics for the prevention 
of FAD. Regardless of the pathogenic form of Aβ, rescuing deficient carboxypeptidase 
function so the mutant enzyme works more like the wild-type enzyme should be beneficial 
to those carrying these mutations. Presenilin mutation carriers are fated to develop this 
devastating form of the disease in mid-life. While only 1–2% of all AD cases are FAD, this 
still represents many tens of thousands of individuals who otherwise currently have no hope 
of escaping this fate. The discovery of the specific biochemical defect of FAD-mutant γ-
secretase paves the way for drug discovery efforts specifically for FAD.
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Figure 1. Production of Aβ from APP.
APP is an integral membrane protein, with the Aβ portion derived in part from the single 
transmembrane domain. β-Secretase is a membrane-tethered aspartyl protease in the pepsin 
family that cleaves APP outside the membrane to release the large extracellular domain of 
APP (APPs-β). The membrane-bound remnant APP CTF-β) is then cleaved by γ-secretase 
to produce Aβ and the APP intracellular domain (AICD). γ-Secretase a membrane-
embedded aspartyl protease composed of four different membrane proteins. Presenilin 
NTF/CTF heterodimer (blue) is the catalytic component of the γ-secretase complex that 
carries out proteolysis within the APP transmembrane domain.
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Figure 2. Processive proteolysis of the APP transmembrane domain by γ-secretase.
An endoproteolytic activity of the enzyme cleaves at the ε site within the transmembrane 
domain close to the membrane-cytosol interface to give long Aβ peptides Aβ48 and Aβ49 
and the APP intracellular domain (AICD). The carboxypeptidase activity of γ-secretase then 
trims Aβ48 and Aβ49 in 3–4 amino acid increments.
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Figure 3. Dual-pathway proteolysis of APP by γ-secretase.
Cleavage at the ε site occurs at one of 2 sites, resulting in Aβ49 and AICD50–99 or Aβ48 
and AICD49–99. Subsequent carboxypeptidase trimming leads to two Aβ product lines: 
Aβ49→Aβ46→Aβ43→Aβ40 and Aβ48→Aβ45→Aβ42→Aβ38.
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